Automated Red Blood Cell Exchange Shows Potential to Improve Sickle Cell Disease Management

Research conducted at the University of York found that automated red blood cell exchange (aRBCX) transfusions can improve the control and management of sickle cell disease (SCD) compared to manual RBC exchange (mRBCX). The study estimated the lifetime clinical and economic impact of aRBCX versus mRBCX in two United Kingdom-based populations with SCD. The findings suggest that aRBCX can reduce acute clinical events by 19%, decrease the time spent receiving chelation therapy, and lower total lifetime costs.

Key Takeaways:

• aRBCX reduced acute clinical events by 19% in both populations with SCD versus mRBCX.
• aRBCX reduced the time spent receiving chelation therapy by 63 and 32 months for paediatric-initiated and adult-initiated individuals, respectively.
• aRBCX lowered total lifetime DMT costs by £71,217 and £30,740 for paediatric-initiated and adult-initiated individuals, respectively.
• aRBCX increased quality-adjusted life years (QALYs) by 0.29 and 0.24 for paediatric-initiated and adult-initiated individuals, respectively.
• aRBCX reduced costs by £112,811 and £61,895 for paediatric-initiated and adult-initiated individuals, respectively.
• The study used individual patient-level simulation modeling to estimate lifetime clinical and economic outcomes.
• The research was conducted in two United Kingdom-based populations with SCD: pediatric and adult.

Statistics:

• 7.74 million people worldwide are affected by SCD (Source: The Economic and Clinical Impact of Recurring Automated Red Blood Cell Exchange to Manage Sickle Cell Disease in the UK).
• aRBCX reduced acute clinical events by 19% (Source: The Economic and Clinical Impact of Recurring Automated Red Blood Cell Exchange to Manage Sickle Cell Disease in the UK).
• aRBCX reduced the time spent receiving chelation therapy by 63 and 32 months for paediatric-initiated and adult-initiated individuals, respectively (Source: The Economic and Clinical Impact of Recurring Automated Red Blood Cell Exchange to Manage Sickle Cell Disease in the UK).
• aRBCX lowered total lifetime DMT costs by £71,217 and £30,740 for paediatric-initiated and adult-initiated individuals, respectively (Source: The Economic and Clinical Impact of Recurring Automated Red Blood Cell Exchange to Manage Sickle Cell Disease in the UK).

Sources:

• NewsRx (2025). Findings in the Area of Sickle Cell Anemia Reported from University of York (The Economic and Clinical Impact of Recurring Automated Red Blood Cell Exchange to Manage Sickle Cell Disease in the UK). Hematology Week. October 20, 2025; p 177.
• The Economic and Clinical Impact of Recurring Automated Red Blood Cell Exchange to Manage Sickle Cell Disease in the UK. PharmacoEconomics - Open, 2025.